tetano
Editor, Senior Moderator
Vaccine
. 2022 Nov 18;S0264-410X(22)01415-3.
doi: 10.1016/j.vaccine.2022.11.020. Online ahead of print.
COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease - A cross-sectional study in Hungary
Monika Fekete[SUP] 1 [/SUP], Alpar Horvath[SUP] 2 [/SUP], Balazs Santa[SUP] 3 [/SUP], Gabor Tomisa[SUP] 4 [/SUP], Gergo Szollosi[SUP] 5 [/SUP], Zoltan Ungvari[SUP] 6 [/SUP], Vince Fazekas-Pongor[SUP] 1 [/SUP], David Major[SUP] 1 [/SUP], Stefano Tarantini[SUP] 6 [/SUP], Janos Tamas Varga[SUP] 7 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus infection is a particular risk for patients with chronic obstructive pulmonary disease (COPD), because they are much more likely to become severely ill due to oxygen supply problems. Primary prevention, including COVID-19 vaccination is of paramount importance in this disease group. The aim of our study was to assess COVID-19 vaccination coverage in COPD patients during the first vaccination campaign of the COVID-19 pandemic.
Methods: A cross-sectional observational study (CHANCE) has been conducted in COPD patients in the eastern, western and central regions of Hungary from 15th November 2021. The anthropometric, respiratory function test results and vaccination status of 1,511 randomly selected patients were recorded who were aged 35 years and older.
Results: The median age was 67 (61-72) years, for men: 67 (62-73) and for women: 66 (60-72) years, with 47.98 % men and 52.02 % women in our sample. The prevalence of vaccination coverage for the first COVID-19 vaccine dose was 88.62 %, whereas 86.57 % of the patients received the second vaccine dose. When unvaccinated (n = 172) and double vaccinated (n = 1308) patients were compared, the difference was significant both in quality of life (CAT: 17 (12-23) vs 14 (10-19); p < 0.001) and severity of dyspnea (mMRC: 2 (2-2) vs 2 (1-2); p = 0.048). The COVID-19 infection rate between double vaccinated and unvaccinated patients was 1.61 % vs 22.67 %; p < 0.001 six months after vaccination. The difference between unvaccinated and vaccinated patients was significant (8.14 % vs 0.08 %; p < 0.001) among those with acute COVID-19 infection hospitalized. In terms of post-COVID symptoms, single or double vaccinated patients had significantly fewer outpatient hospital admissions than unvaccinated patients (7.56 vs 0 %; p < 0.001).
Conclusion: The COVID-19 vaccination coverage was satisfactory in our sample. The uptake of COVID-19 vaccines by patients with COPD is of utmost importance because they are much more likely to develop severe complications.
Keywords: CAT; COVID-19; Chronic obstructive pulmonary disease (COPD); SARS coronavirus; Vaccination; mMRC.
. 2022 Nov 18;S0264-410X(22)01415-3.
doi: 10.1016/j.vaccine.2022.11.020. Online ahead of print.
COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease - A cross-sectional study in Hungary
Monika Fekete[SUP] 1 [/SUP], Alpar Horvath[SUP] 2 [/SUP], Balazs Santa[SUP] 3 [/SUP], Gabor Tomisa[SUP] 4 [/SUP], Gergo Szollosi[SUP] 5 [/SUP], Zoltan Ungvari[SUP] 6 [/SUP], Vince Fazekas-Pongor[SUP] 1 [/SUP], David Major[SUP] 1 [/SUP], Stefano Tarantini[SUP] 6 [/SUP], Janos Tamas Varga[SUP] 7 [/SUP]
Affiliations
- PMID: 36424256
- DOI: 10.1016/j.vaccine.2022.11.020
Abstract
Introduction: Coronavirus infection is a particular risk for patients with chronic obstructive pulmonary disease (COPD), because they are much more likely to become severely ill due to oxygen supply problems. Primary prevention, including COVID-19 vaccination is of paramount importance in this disease group. The aim of our study was to assess COVID-19 vaccination coverage in COPD patients during the first vaccination campaign of the COVID-19 pandemic.
Methods: A cross-sectional observational study (CHANCE) has been conducted in COPD patients in the eastern, western and central regions of Hungary from 15th November 2021. The anthropometric, respiratory function test results and vaccination status of 1,511 randomly selected patients were recorded who were aged 35 years and older.
Results: The median age was 67 (61-72) years, for men: 67 (62-73) and for women: 66 (60-72) years, with 47.98 % men and 52.02 % women in our sample. The prevalence of vaccination coverage for the first COVID-19 vaccine dose was 88.62 %, whereas 86.57 % of the patients received the second vaccine dose. When unvaccinated (n = 172) and double vaccinated (n = 1308) patients were compared, the difference was significant both in quality of life (CAT: 17 (12-23) vs 14 (10-19); p < 0.001) and severity of dyspnea (mMRC: 2 (2-2) vs 2 (1-2); p = 0.048). The COVID-19 infection rate between double vaccinated and unvaccinated patients was 1.61 % vs 22.67 %; p < 0.001 six months after vaccination. The difference between unvaccinated and vaccinated patients was significant (8.14 % vs 0.08 %; p < 0.001) among those with acute COVID-19 infection hospitalized. In terms of post-COVID symptoms, single or double vaccinated patients had significantly fewer outpatient hospital admissions than unvaccinated patients (7.56 vs 0 %; p < 0.001).
Conclusion: The COVID-19 vaccination coverage was satisfactory in our sample. The uptake of COVID-19 vaccines by patients with COPD is of utmost importance because they are much more likely to develop severe complications.
Keywords: CAT; COVID-19; Chronic obstructive pulmonary disease (COPD); SARS coronavirus; Vaccination; mMRC.